SCHEMBL6205296

SCHEMBL6205296

Cc1csc(-c2ccccc2NC(=O)OCC2(F)CCNCC2)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM3 P20309 10/20 0.41
CHRM1 P11229 6/20 0.41
CHRM2 P08172 5/20 0.41
TYK2 P29597 2/20 0.37
ADRA1A P35348 1/20 0.37
ACHE P22303 2/20 0.36
MAOA P21397 1/20 0.36
MAPK1 P28482 1/20 0.36
MEN1 O00255 1/20 0.35
NPC1 O15118 1/20 0.35
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
HPGD P15428 1/20 0.35
ALOX15 P16050 1/20 0.35
CASP1 P29466 1/20 0.35
RAB9A P51151 1/20 0.35
CASP7 P55210 1/20 0.35
KMT2A Q03164 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
HSD17B10 Q99714 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL828973 0.80 CHRM3 (0.65) CHRM3CHRM1CHRM2
Hydrochloric Acid SCHEMBL828972 0.79 CHRM3 (0.64) CHRM3CHRM1CHRM2
SCHEMBL828429 0.76 CHRM3 (0.63) CHRM3CHRM1CHRM2TYK2
SCHEMBL6416762 0.73 CHRM3 (0.45) CHRM3CHRM1CHRM2
SCHEMBL6228886 0.73 CHRM3 (0.45) CHRM3CHRM1CHRM2
SCHEMBL4662449 0.72 ACHE (0.55) ACHEMAOAMAPK1NPC1ALDH1A1
SCHEMBL6205305 0.70 CHRM3 (0.39) CHRM3CHRM1CHRM2TYK2KMT2A
SCHEMBL6204531 0.70 CHRM3 (0.60) CHRM3CHRM1CHRM2
SCHEMBL6202027 0.69 CHRM3 (0.64) CHRM3CHRM1CHRM2
SCHEMBL6204696 0.69 CHRM3 (0.64) CHRM3CHRM1CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050277676-A1 M3muscarinic acetylcholine receptor antagonists GLAXO GROUP LIMITED (GB) 2005-12-15 US claimed
EP-1549278-A4 M sb 3 /sb MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS GLAXO GROUP LTD (GB) 2005-12-14 EP claimed
EP-1549278-A2 M sb 3 /sb MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS GLAXO GROUP LIMITED (GB) 2005-07-06 EP claimed
WO-2004012684-A2 M3MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS GLAXO GROUP LIMITED (GB) 2004-02-12 WO claimed
US-20050277676-A1 M3muscarinic acetylcholine receptor antagonists GLAXO GROUP LIMITED (GB) 2005-12-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050277676-A1 M3muscarinic acetylcholine receptor antagonists CHRM3, CHRM2, CHRM5 CHRM3 1/4885CHRM1 8/4885CHRM2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.